We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Collaboration Initiated to Accelerate Use of Genomics Research for Medical Applications

By LabMedica International staff writers
Posted on 31 Mar 2009
Applied Biosystems (Carlsbad, CA, USA), a division of Life Technologies Corp., and the Translational Genomics Research Institute (TGen; Phoenix, AZ, USA) have announced a strategic alliance designed to accelerate research into complex diseases and medical disorders.

As part of this alliance, a team of scientists from TGen and Applied Biosystems will employ the SOLiD 3 system, Applied Biosystems' next-generation genomic analysis platform, to sequence DNA from thousands of patients with a variety of diseases. The aim of this research is to convert scientific discoveries at the genetic level into knowledge about the underlying causes of disease, advancing the potential of personalized medicine by reducing the cost of genome sequencing to make it a common diagnostic tool in medical care.

The scientists involved in this alliance will use a total of five SOLiD 3 systems to build a sequencing pipeline in connection with patient centric, medically directed resequencing on a cross-section of patient samples. The results are expected to positively impact individuals with cancer, autoimmune, and neurologic disorders. The alliance will also involve the codevelopment of a bioinformatics analysis and visualization pipeline for the SOLiD platform. This will result in software tools designed to ease the challenges associated with analyzing the vast amounts of data generated by human disease and cancer genomics applications of next generation sequencing.

The scientists at TGen chose the SOLiD technology for this project because of its inherent scalability, remarkable throughput and data accuracy. These attributes make the SOLiD system uniquely suited for translational research of complicated diseases by enabling the detection of single nucleotide polymorphisms and other structural variation across the genome in large numbers of samples. The technology is for research use only; it is not for use in diagnostic procedures.

Related Links:
Applied Biosystems
Translational Genomics Research Institute



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Sepsis Test
SeptiCyte RAPID
New
All-in-One Molecular System
AIO M160

Latest BioResearch News

Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
31 Mar 2009  |   BioResearch

International Consensus Standardizes Tumor Microbiota Detection and Reporting
31 Mar 2009  |   BioResearch

Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
31 Mar 2009  |   BioResearch